{"id":"W2965053910","doi":"10.1200/jco.2012.30.15_suppl.8587","title":"A phase II, multicenter, open-label study of YM155 plus docetaxel in subjects with stage III (unresectable) or stage IV melanoma.","year":2012,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Treatment and Pharmacology","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Regional Cancer Foundation","funders":"","keywords":"Docetaxel; Medicine; Tolerability; Clinical endpoint; Internal medicine; Phases of clinical research; Oncology; Melanoma; Gastroenterology; Survivin; Survival rate; Progression-free survival; Surgery; Chemotherapy; Adverse effect; Clinical trial; Cancer; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001824278,0.001805936,0.002433732,0.0005392213,0.0005156148,0.000827542,0.0009484189,0.001099959,0.004313396],"category_scores_gemma":[0.0009580895,0.000804681,0.0009854406,0.0004327614,0.0009386797,0.0007878401,0.0003423001,0.002448959,0.001381118],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008794713,"about_ca_system_score_gemma":0.001514036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001498491,"about_ca_topic_score_gemma":0.003410175,"domain_scores_codex":[0.9995179,0.0002490861,0.00002172218,0.00008069308,0.00003646937,0.00009415029],"domain_scores_gemma":[0.9993482,0.00009143758,0.0001120015,0.00003766854,0.00004517855,0.0003654724],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8099021,0.09513813,0.007517495,0.0008237037,0.001131834,0.0003085974,0.0003994545,0.001214135,0.0268673,0.0001773172,0.003781249,0.05273864],"study_design_scores_gemma":[0.6178979,0.3677035,0.01031439,0.00002650936,0.0003455727,0.0001154746,0.0000610153,0.0005877636,0.001190664,0.00009132346,0.00164644,0.00001940263],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908931,0.001842717,0.0005618199,0.0002955077,0.0002106839,0.003921462,0.0008139526,0.00008743948,0.001373186],"genre_scores_gemma":[0.9866152,0.001902694,0.001506018,0.0009710675,0.0003291286,0.00356034,0.00167695,0.00002919957,0.003409335],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004313396,"threshold_uncertainty_score":0.01442981,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2834801746337777,"score_gpt":0.5572430561771021,"score_spread":0.2737628815433245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}